Related Experiment Video
Updated: Dec 18, 2025

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Clinical diagnosis of Lewy body dementia
Ajenthan Surendranathan1, Joseph P M Kane2, Allison Bentley3
1Ajenthan Surendranathan, Department of Psychiatry, University of Cambridge, UK.
Background:
Lewy body dementia, consisting of both dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), is considerably under-recognised clinically compared with its frequency in autopsy series.
Aims:
This study investigated the clinical diagnostic pathways of patients with Lewy body dementia to assess if difficulties in diagnosis may be contributing to these differences.
Method:
We reviewed the medical notes of 74 people with DLB and 72 with non-DLB dementia matched for age, gender and cognitive performance, together with 38 people with PDD and 35 with Parkinson's disease, matched for age and gender, from two geographically distinct UK regions.
Results:
The cases of individuals with DLB took longer to reach a final diagnosis (1.2 v. 0.6 years, P = 0.017), underwent more scans (1.7 v. 1.2, P = 0.002) and had more alternative prior diagnoses (0.8 v. 0.4, P = 0.002), than the cases of those with non-DLB dementia. Individuals diagnosed in one region of the UK had significantly more core features (2.1 v. 1.5, P = 0.007) than those in the other region, and were less likely to have dopamine transporter imaging (P < 0.001). For patients with PDD, more than 1.4 years prior to receiving a dementia diagnosis: 46% (12 of 26) had documented impaired activities of daily living because of cognitive impairment, 57% (16 of 28) had cognitive impairment in multiple domains, with 38% (6 of 16) having both, and 39% (9 of 23) already receiving anti-dementia drugs.
Conclusions:
Our results show the pathway to diagnosis of DLB is longer and more complex than for non-DLB dementia. There were also marked differences between regions in the thresholds clinicians adopt for diagnosing DLB and also in the use of dopamine transporter imaging. For PDD, a diagnosis of dementia was delayed well beyond symptom onset and even treatment.
Insights
Diagnosing Lewy body dementia (LBD) is complex and lengthy, often involving multiple misdiagnoses and scans. Parkinson's disease dementia (PDD) diagnosis is also delayed, impacting patient care.
Area of Science:
- Neurology
- Geriatric Medicine
- Neuroscience
Background:
- Lewy body dementia (LBD), encompassing dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), is frequently underdiagnosed compared to its prevalence.
- Clinical recognition of LBD often lags behind findings in post-mortem studies.
Purpose of the Study:
- To investigate the clinical diagnostic pathways for patients with Lewy body dementia.
- To determine if diagnostic challenges contribute to the under-recognition of LBD.
Main Methods:
- Retrospective review of medical records from two UK regions.
- Comparison of 74 DLB cases with 72 non-DLB dementia cases (matched for age, gender, cognitive performance).
- Analysis of 38 PDD cases and 35 Parkinson's disease cases (matched for age, gender).
Main Results:
- DLB diagnosis took significantly longer (1.2 vs. 0.6 years) and involved more scans and prior misdiagnoses compared to non-DLB dementia.
- Regional variations observed in core LBD features and use of dopamine transporter imaging.
- For PDD, dementia diagnosis was delayed, with many patients showing cognitive impairment and receiving dementia medication over a year prior to formal diagnosis.
Conclusions:
- The diagnostic pathway for DLB is more protracted and complex than for other dementias.
- Significant regional disparities exist in DLB diagnostic criteria and the utilization of dopamine transporter imaging.
- Diagnosis of dementia in PDD is often substantially delayed, occurring long after symptom onset and even treatment initiation.
More Related Videos
10:03Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Related Concept Videos
Dementia
The progression of dementia is generally gradual....
Parkinson's Disease: Overview
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Neural Regulation
Lysosomal Hydrolases
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...